CAMBRIDGE, Mass., June 24, 2002 (PRIMEZONE) -- Genomic Profiling Systems, Inc. (GPS), a developer of rapid microbial tests for the industrial microbiology market, today announced that Steven Buhl, Ph.D. has joined the company as Vice President of Development.
With over 20 years of experience in the diagnostic and healthcare industries, Dr. Buhl has led efforts to convert product concepts into commercial products for SomaLogic, Abaxis, and Technicon Instruments (acquired by Bayer), and is co-author of ten U.S. patents. At SomaLogic, he identified and specified chip production parameters for use in proteomic in vitro diagnostic devices. At Abaxis, Dr. Buhl developed the blood analyzer that is still the leading revenue source for Abaxis ten years later.
Bob Linke, President & CEO of GPS, commented: "Steve's role at GPS is critical since we have entered the product development phase. In the short time he has been with the company, he has enabled us to identify and address the key areas that will help us bring our products to market as quickly as possible. Given his successful track record and entrepreneurial drive, we are confident that Steve will help us achieve our goal of becoming a leader in the industrial microbiology market."
"We hired Steve to be the foundation of our product development effort," noted Don Straus, Ph.D., Founder and Chief Science Officer of GPS. "He compliments our in-house strengths by bringing decades of product development experience to GPS. Most importantly, Steve's expertise is taking novel proof-of-principle stage projects, turning them into superior commercialized products and getting them to market quickly. Steve has a unique fit with GPS because he not only has deep and relevant product development experience, but he has gained this experience at multiple early stage companies like ours.
"GPS was particularly attractive to me because the company understands that focusing on the needs of its customers is vital to the success of product development and its long term success," said Dr. Buhl, the new VP of Development. "GPS' suite of technologies will revolutionize the entire business process of its customers. Industrial companies are continually searching for ways to reduce inventory costs and improve manufacturing efficiencies. By using GPS's rapid ultra-sensitive microbial detection products, companies in the pharmaceutical, food and beverage industries will be able to meet these key business objectives."
Dr. Buhl holds a B.S. in Chemistry from Adams State College of Colorado and a Doctorate in Biomedical Sciences from Oak Ridge Graduate School of Biomedical Sciences, University of Tennessee.
About Genomic Profiling Systems, Inc.
Genomic Profiling Systems, Inc. (GPS), based in Cambridge, Massachusetts, is a diagnostics company that is addressing significant unmet needs for rapid microbial analysis in the industrial microbiology market. GPS has developed a suite of proprietary Direct Imaging(tm) technologies for detecting and identifying microscopic targets (e.g., bacteria, viruses, proteins, and DNA) based on large-area digital imaging. GPS's technologies enable commercialization of tests that capture ambitious specifications (e.g., speed, ultra-sensitivity and quantification) but are simple, cost-effective, and user-friendly. The Company's first products target the rapid testing needs of pharmaceutical, food and beverage companies and should result in significant reductions in inventory costs and substantial improvements in manufacturing efficiencies. GPS's pipeline of future products targets the need for ultra-sensitive, rapid point-of-care tests that detect multiple disease-causing agents in industrial microbiology and healthcare.